Free Trial

Check-Cap Q1 2023 Earnings Report

Check-Cap logo
$1.23 -0.07 (-5.38%)
As of 04:00 PM Eastern

Check-Cap EPS Results

Actual EPS
-$0.76
Consensus EPS
-$0.55
Beat/Miss
Missed by -$0.21
One Year Ago EPS
N/A

Check-Cap Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Check-Cap Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Check-Cap Earnings Headlines

Check-Cap (NASDAQ:CHEK) Coverage Initiated by Analysts at StockNews.com
24/7 Automated Profits in Crypto
What if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast world of passive crypto income, where you set up a dependable income stream that works for you, whether you're at your computer or living your life.
See More Check-Cap Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Check-Cap? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Check-Cap and other key companies, straight to your email.

About Check-Cap

Check-Cap (NASDAQ:CHEK), a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.

View Check-Cap Profile

More Earnings Resources from MarketBeat